Immunomedics, Inc. and Nycomed GmbH announced that they have been talkin about a collaboration agreement. Nycomed GmbH wants to manufacture and commercialize veltuzumab, Immunomedics' antibody drug for non-cancer diseases. Immunomedics asked for an initial $40 million, and payments of up to $580 million after sales begin.